Immunological factors in cirrhosis diseases from a bibliometric point of view

Table 1 Publications in the 10 most productive countries/regions

Rank	Country/region	Year	Count (%)	Centrality
1	United States	2003	781 (27.18%)	0.36
2	China	2003	538 (18.73%)	0.06
3	Germany	2003	300 (10.44%)	0.17
4	Italy	2003	259 (9.01%)	0.19
5	Japan	2003	192 (6.68%)	0.03
6	England	2003	186 (6.47%)	0.20
7	Spain	2003	157 (5.46%)	0.09
8	France	2003	132 (4.59%)	0.17
9	Australia	2004	85 (2.96%)	0.12
10	Canada	2003	84 (2.92%)	0.12

Table 2 Publications in the 10 most productive institutions

Rank	Institution	Year	Count (%)	Centrality
1	Univ Calif Davis (United States)	2004	65 (2.26%)	0.12
2	Mayo Clin (United States)	2007	47 (1.64%)	0.02
3	Zhejiang Univ (China)	2011	44 (1.53%)	0.01
4	Univ Birmingham (England)	2009	38 (1.32%)	0.04
5	Univ Calif San Diego (United States)	2009	28 (0.97%)	0.07
6	Yale Univ (United States)	2007	26 (0.90%)	0.06
7	Inst Salud Carlos III (Spain)	2008	25 (0.87%)	0.06
8	Univ Milan (Italy)	2004	24 (0.84%)	0.06
9	Univ Barcelona (Spain)	2003	23 (0.80%)	0.03
10	Emory Univ (United States)	2006	23 (0.80%)	0.05

Table 3 Top 10 authors and co-cited authors

Rank	Author	Count (%)	Centrality	Co-cited author	Co-citation	Centrality
1	Gershwin M Eric (United States)	42 (1.46%)	0.02	Friedman Scott L (United States)	337	0.05
2	Tacke Frank (Germany)	27 (0.94%)	0.01	Bataller Ramon (United States)	235	0.06
3	Trautwein Christian (Germany)	20 (0.70%)	0.01	Seki Ekihiro (United States)	204	0.05
4	Weiskirchen Ralf (Germany)	13 (0.45%)	0	Tilg Herbert (Austria)	141	0.07
5	Hirschfield Gideon M (Canada)	11 (0.38%)	0.01	Wynn Tomas A (United States)	140	0.02
6	Friedman Scott L (United States)	9 (0.31%)	0	Albillos Agustín (Spain)	128	0.01
7	Such Jose (Spain)	9 (0.31%)	0	Szabo Gyongyi (United States)	126	0.04
8	Szabo Gyongyi (United States)	8 (0.28%)	0	Gao Bin (United States)	125	0.08
9	Invernizzi Pietro (Italy)	8 (0.28%)	0	Hirschfield Gideon M (Canada)	120	0.09
10	Czaja Albert J (United States)	8 (0.28%)	0	Li J (China)	116	0.02

Table 4 Top 10 journals and co-cited journals for research of immunological factors in cirrhosis

Rank	Journal	Count (%)	IF (2021)	JCR	Co-cited Journal	Citation	IF (2021)	JCR
1	World Journal of Gastroenterology	113 (3.928%)	5.374	Q2	Hepatology	2409	17.298	Q1
2	Hepatology	109 (3.790%)	17.298	Q1	Journal of Hepatology	2124	30.083	Q1
3	Frontiers in immunology	73 (2.540%)	8.786	Q1	Gastroenterology	1988	33.883	Q1
4	Journal of Hepatology	70 (2.430%)	30.083	Q1	Gut	1369	31.793	Q1
5	Liver International	59 (2.050%)	8.754	Q1	Journal Of Clinical Investigation	1301	19.456	Q1
6	PLoS One	57 (1.980%)	3.752	Q2	Journal Of Immunology	1280	5.426	Q2
7	International Journal of Molecular Sciences	46 (1.600%)	6.208	Q1	The New England Journal of Medicine	1240	176.079	Q1
8	Gastroenterology	35 (1.220%)	33.883	Q1	Proceedings of the National Academy of Sciences of the United States of America	1221	12.779	Q1
9	Seminars in Liver Disease	32 (1.110%)	6.512	Q2	PLoS One	1183	3.752	Q2
10	Hepatology Research	30 (1.040%)	4.942	Q2	Lancet	1153	202.731	Q1

IF: Impact factors; JCR: Journal Citation Reports.

Table 5 Top 10 co-cited references on research of immunological factors in cirrhosis

Rank	Reference	Year	Journal	Citation	Centrality
1	Mechanisms of hepatic stellate cell activation	2017	Nature Reviews Gastroenterology & Hepatology	50	0.03
2	Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance	2014	Journal of Hepatology	46	0.02
3	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection	2017	Journal of Hepatology	35	0.03
4	Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis	2013	Gastroenterology	35	0.03
5	Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries	2018	CA: A Cancer Journal for Clinicians	33	0.02
6	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial	2017	Lancet	33	0.04
7	Immunology in the liver-from homeostasis to disease	2016	Nature Reviews Gastroenterology & Hepatology	32	0.14
8	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure	2016	Hepatology	31	0.07
9	Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants	2009	The New England Journal of Medicine	31	0.02
10	TLR4 enhances TGF-beta signaling and hepatic fibrosis	2007	Nature Medicine	31	0.06

Table 6 Top 20 keywords on research of immunological factors in cirrhosis

Rank	Keyword	Occurrences	Total link strength	Rank	Keyword	Occurrences	Total link strength
1	Fibrosis	428	2558	11	Liver	225	1276
2	Cirrhosis	423	2483	12	Risk factors	221	1200
3	Inflammation	384	2438	13	Infection	184	1123
4	Liver fibrosis	381	2290	14	Necrosis factor alpha	160	1001
5	Expression	340	1884	15	T cells	155	923
6	Hepatocellular carcinoma	309	1895	16	Cells	143	770
7	Activation	234	1421	17	Regulatory t cells	140	863
8	Primary biliary cirrhosis	232	1268	18	Liver cirrhosis	133	770
9	Disease	231	1355	19	Growth factor beta	130	834
10	Hepatic stellate cells	228	1525	20	Oxidative stress	129	836